On June 20, 2017, Imagion Biosystems President and CEO Bob Proulx provided an update and briefing on the pending Imagion Biosystems initial public offering on the Australian Securities Exchange. An audio recording of the call is now available for listening:
Quarterly Activity Report – Quarter ending 31 December 2023
January 31, 2024
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal